Sa!Vy Diary (L.H.C.) - La Stock Del XXXIV Secolo !!! - Pagina 157
Mes Fondo salva-stati, da Camera ok a risoluzione governo. Infuria #stopMes, ma Borghi smentisce Salvini
Continua a infuriare su Twitter l'hashtag #stopMes, nel giorno in cui la Camera dà l'ok alla risoluzione della maggioranza. Il testo è stato approvato a Montecitorio con 291 voti a …
Maxi-piano green dell’UE, ecco i titoli ‘verdi’ di Piazza Affari che esultano
Nel giorno in cui la rivista Time annuncia che l’attivista climatica Greta Thunberg è il personaggio dell’anno per il 2019, l’UE dettaglia quella che nei prossimi anni sarà una vera …
Aspettando la ‘prima’ di Lagarde alla Bce: la carta greca fa di nuovo meglio dei BTP
Alla vigilia della prima di Christine Lagarde come presidente della Bce, indicazioni sulla carta italiana sono arrivate dall’asta dei Bot a un anno, che ha messo in evidenza rendimenti ancora …
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #1561
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    2❤11&More (Frattali,Frattaglie,Frittate,Franchige, Futures) ...

    [email protected]❣Ψ€ A TUTTI

    ... . ... i miei auguri ... qui
    ... . ... la colonna sonora di
    fine/principio ... qui & qui



    ☻/♫♪ ۞ [email protected]❣♆¥.pk Alert ۞ P▲ℕ❣☪ €MP¥R€
    /▌
    / \
    Leggi/Read: [email protected]❣♆¥ ♥ ® █║▌│█│║▌║▌║│█ © ❤ DISCLAIMER, IMO & Manthra
    Trading-Station - New F.o.L. Order
    K€SADDhAPHA'pe'KAMPA' €MP¥R€ $0UND $¥$T€M$ ❣❣❣
    [email protected]❣♆¥ €MP¥R€ $0UND $¥$T€M$ ♫ ❤® █║▌│█│║▌║▌║│█ ©❤ ♫

  2. #1562

    Data Registrazione
    Dec 2008
    Messaggi
    3,849
    Mentioned
    0 Post(s)
    Quoted
    3 Post(s)
    Potenza rep
    42949683
    Sal.Vi......= UN MITO.........

  3. #1563
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    [email protected]❣♆¥ ♥ ® █║▌│█│║▌║▌║│█ © ❤


  4. #1564
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    BIO2❤12&More (Frattali,Frattaglie,Frittate,Franchige, Futures) ...

    [email protected]❣Ψ€ A TUTTI
    ۞

    Avian FLU.

    Aviaria/ Prima vittima in Cina in 18 mesi: "Ma niente panico"

    Pechino, 2 gen. (TMNews) - Le autorità sanitarie della metropoli di Shenzhen, nel sud della Cina, hanno chiesto alla popolazione locale di evitare scene di panico dopo la morte di una persona che aveva contratto il virus H5N1 responsabile dell'influenza aviaria. Si tratta del primo decesso nel paese in 18 mesi.
    Il Centro di controllo delle malattie di Shenzhen ha confermato che la vittima era stata in contatto con un volatile, ma non è ancora chiaro il modo in cui è stato contratto il virus.
    "Il virus non può propagarsi tra le persone. Non serve che i cittadini di Shenzhen entrino in una fase di panico", ha dichiarato il centro.
    La vittima, 39 anni, era stata colpita da febbre alta lo scorso 21 dicembre. Da allora, e prima di scoprire che aveva contratto il virus H5N1, era entrata in contatto con circa 120 persone, che non presentano alcun sintomo tipico dell'influenza aviaria.



    Spero almeno minimamente utile; in caso di interesse (€uribor free).



    ☻/♫♪ ۞ BIO-crack Alert ۞ P▲ℕ❣☪ €MP¥R€
    /▌
    / \
    Leggi/Read: [email protected]❣♆¥ ♥ ® █║▌│█│║▌║▌║│ █ © ❤ DISCLAIMER, IMO & Manthra
    Trading-Station - New F.o.L. Order
    K€SADDhAPHA'pe'KAMPA' BioPresto-€MP¥R€ $0UND $¥$T€M$ ❣❣❣
    [email protected]❣♆¥ €MP¥R€ $0UND $¥$T€M$ ♫ ❤® █║▌│█│║▌║▌║ █ ©❤ ♫

  5. #1565
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    2❤12&More (Frattali,Frattaglie,Frittate,Franchige, Futures) ...

    Ultima modifica di Sal.Vi; 03-01-12 alle 16:50 Motivo: ❣ format & text corrections ❣

  6. #1566
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    Bio2❤12&More(Frattali.Frattaglie.Fritt at e.Franchige.Franchi.Futures.Féssy)


    Profile & Board -- REUT-Fin.Data -- YHOO Fin.Data -- FINVIZ-Fin.Data -- BARCH-Fin.Data -- GOOG Fin.Data -- ZACK Fin.Data -- Y-Fin.Data
    SEC -- Owners -- Insiders -- Short-data -- Options -- Analysts -- NewsByGOOG -- Tech.Rev.Bar.Ch. -- NewsByIDRA & I.R. -- Products

    Idera Pharmaceuticals, Inc. is engaged in the discovery and development of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA)-based drug candidates targeted to Toll-Like Receptors (TLRs), to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. TLRs are specific receptors present in immune system cells that recognize the DNA or RNA of bacteria or viruses and initiate an immune response. The Company has designed and created TLR agonists and antagonists to modulate immune responses. The Company collaborates with pharmaceutical companies to advance other applications of its TLR-targeted compounds. As of December 31, 2010, the Company collaborated with Merck KGaA for cancer treatment, excluding cancer vaccines, and with Merck Sharp & Dohme Corp, for vaccine adjuvants in the fields of cancer, infectious diseases, and Alzheimer’s disease.

    The Company’s IMO-2125, is a synthetic DNA-based TLR9 agonist, which is its lead candidate for the treatment of chronic hepatitis C virus (HCV) infection. In preclinical models, including cultures of human immune cells and in nonhuman primates, IMO-2125 induced high levels of natural interferon and other antiviral proteins. As of December 31, 2010, the Company was conducting two Phase I clinical trials of IMO-2125, in patients with HCV, infection. In its first Phase I trial, the Company is evaluating IMO-2125 in patients with chronic HCV infection who had no response to a prior regimen of the current standard of care therapy. The second Phase I clinical trial of IMO-2125 is in combination with ribavirin in patients with chronic HCV infection who have not received prior treatment for their HCV infection. It has initiated the trial in October 2009. In this clinical trial, patients will receive IMO-2125 or a control article by subcutaneous injection once per week for four weeks at escalating dose levels in combination with daily oral administration of standard doses of ribavirin. As of December 31, 2010, the clinical trial was conducted at sites in France, Russia and Hungary. In addition to the Company’s TLR9 agonists, such as IMO-2125, it has developed synthetic RNA-based compounds that mimic viral RNA and induce immune responses by functioning as agonists of TLR7 and/or TLR8.

    In December 2010, the Company announced interim results from a Phase 1 clinical trial of IMO-2125 combined with ribavirin in treatment-naive patients with chronic HCV infection. IMO-2125 was well tolerated by all patients in the four cohorts. IMO-2125-treated patients showed dose-dependent increases in natural interferon-alpha and other antiviral proteins. In April 2010, the Company presented preclinical data, which showed that treatment with a TLR7/TLR9 antagonist compound reduced symptoms of atherosclerosis in a mouse model. In November 2010, it presented results from studies demonstrating dose-dependent reduction of cardiovascular disease markers by a TLR7/TLR9 antagonist in hyperlipidemic mice. In November 2010, the Company also presented preclinical data showing that once-weekly doses of a TLR7/TLR9 antagonist, IMO-3100, in non-human primates led to sustained suppression of TLR7- and TLR9-mediated immune responses over four weeks of treatment and presented results from a preclinical study in which blood cells from healthy females produce higher levels of pro-inflammatory cytokines in response to TLR7 stimulation than do blood cells from healthy male subjects. In February 2011, it presented additional data from studies in mice that are genetically predisposed to develop autoimmune disease similar to the human autoimmune disease lupus, in which treatment with IMO-3100 suppressed several disease progression parameters.

    In August 2008, the Company selected IMO-3100 as a lead antagonist drug candidate and initiated preclinical development studies. In January 2010, the Company initiated a Phase 1 clinical trial of IMO-3100 in healthy subjects. In October 2010, it announced results from the single-dose Phase 1 clinical trial of IMO-3100. IMO-3100 was well tolerated at all dose levels in the trial. The Company also conducted a four-week multiple-dose Phase 1 clinical trial of IMO-3100 in 24 healthy subjects that it initiated in July 2010 and completed during the year ended December 31, 2010. In this trial, IMO-3100 was administered in two dosing regimens for four weeks, with eight subjects per regimen. Eight additional subjects received placebo injections. The pharmacodynamic mechanism of action is how IMO-3100 engages the immune system in the targeted manner, which it assessed through measurement of the inhibition of TLR7 and TLR9-mediated cytokine induction in peripheral blood mononuculear cells (PBMCs). The trial was conducted at a single United States site.

    In December 2007, the Company entered into a worldwide license agreement with Merck KGaA to research, develop, and commercialize products, containing its TLR9 agonists, including IMO-2055, for the treatment of cancer, excluding cancer vaccines. Merck KGaA refers to IMO-2055 as EMD 1201081. Prior to entering into its agreement with Merck KGaA, the Company had commenced clinical trials of IMO-2055, including a Phase Ib clinical trial of IMO-2055 in patients with non-small cell lung cancer. In January 2009, it initiated a Phase Ib clinical trial of IMO-2055 in patients with colorectal cancer. In December 2009, Merck initiated a Phase II clinical trial of IMO-2055 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. In August 2010, it announced that Merck KGaA initiated a Phase 1b clinical trial of IMO-2055 in treatment of patients with squamous cell carcinoma of the head and neck who had not received any prior cancer therapy and therefore treatment in the trial is referred to as first-line. In December 2007, the Company initiated a Phase 1b clinical trial of IMO-2055 in patients with non-small cell lung cancer whose cancer had progressed during a prior course of standard therapy. In January 2009, the Company initiated a Phase Ib clinical trial of IMO-2055 in combination with Erbitux and chemotherapy in patients with colorectal cancer whose cancer had progressed during a prior course of standard therapy.

    The Company competes with Pfizer, Inc., Dynavax Technologies Corporation, Anadys Pharmaceutical, Inc., Gilead Sciences, Inc., VentiRx Pharmaceuticals, Cytos Biotechnology, Merck, Vertex Pharmaceuticals, Inc., GlaxoSmithKline plc, Pharmasset, Inc., AstraZeneca Pharmaceuticals plc, Pfizer, Inc., Novartis, VaxInnate, Inc., Intercell AG, Sanofi-Aventis Groupe, Celldex Therapeutics, Inc., Bristol-Myers Squibb Company and Biolex Therapeutics, Inc.












    Ultima modifica di Sal.Vi; 14-08-12 alle 11:19 Motivo: ❣ format & text corrections ❣

  7. #1567
    L'avatar di raggirays
    Data Registrazione
    Apr 2010
    Messaggi
    826
    Mentioned
    0 Post(s)
    Quoted
    0 Post(s)
    Potenza rep
    29583509
    Un doveroso & reiterato augurio di buon anno con due postille:

    1. bellissimi i mix di TranceAroundTheWorld, so che i link fanno paura ma dico a tutti, apriteli ogni tanto che fan bene

    2. mi ricordo che in data 2007 (o prima, o dopo, o durante..) avevi dato un target per ASTI di 0.28$$$ quando quotava circa 10 volte tanto, sei il numero 1(uno)!

  8. #1568
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    2❤12&More (Frattali,Frattaglie,Frittate,Franchige, Futures) ...



    Citazione Originariamente Scritto da raggirays Visualizza Messaggio
    Un doveroso & reiterato augurio di buon anno con due postille:

    1. bellissimi i mix di TranceAroundTheWorld, so che i link fanno paura ma dico a tutti, apriteli ogni tanto che fan bene

    2. mi ricordo che in data 2007 (o prima, o dopo, o durante..) avevi dato un target per ASTI di 0.28$$$ quando quotava circa 10 volte tanto, sei il numero 1(uno)!

  9. #1569
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    2❤12&More(Frattali,Frattaglie,Fritt ate,F ranchige,Franchi,Futures,Féssy)...

    [email protected]❣Ψ€ A TUTTI
    ۞ See post n.290 for 3D type ۞

    Q Q Q





    Daily & 4-hourly ema-format of QQQ.
    Graphical contest 'in progress' between bullish H&S vs. bearish multiple top.
    Red-markers (██) as main priceXvolume levels.

    I hope at least minimally useful. In case of interest (€uribor free) ►►►►►►►.




    ☻/♫♪ ۞ [email protected]❣♆¥.pk Alert ۞ P▲ℕ❣☪ €MP¥R€
    /▌
    / \
    Leggi/Read: [email protected]❣♆¥ ♥ ® █║▌│█│║▌║▌║│█ © ❤ DISCLAIMER, IMO & Manthra
    Trading-Station - New F.o.L. Order
    K€SADDhAPHA'pe'KAMPA' €MP¥R€ $0UND $¥$T€M$ ❣❣❣
    [email protected]❣♆¥ €MP¥R€ $0UND $¥$T€M$ ♫ ❤® █║▌│█│║▌║▌║│█ ©❤ ♫
    Immagini Allegate Immagini Allegate Sa!Vy Diary (L.H.C.) - La Stock Del XXXIV Secolo !!!-sa-vyjpg3.jpg Sa!Vy Diary (L.H.C.) - La Stock Del XXXIV Secolo !!!-sa-vyjpg4.jpg 

  10. #1570
    L'avatar di Sal.Vi
    Data Registrazione
    Sep 2008
    Messaggi
    8,382
    Blog Entries
    4
    Mentioned
    0 Post(s)
    Quoted
    2 Post(s)
    Potenza rep
    42949684

    2❤12&More(Frattali,Frattaglie,Fritt ate,F ranchige,Franchi,Futures,Féssy)...

    [email protected]❣Ψ€ A TUTTI


    RILEVANTE RE-INTERPRETAZIONE DELLE STOCKS
    FINANZIARIE, ALLA LUCE DEGLI AVVENIMENTI POST-2007:
    POST n.332
    POST n.334






    BCS:US




    G:IM




    GS:US




    HBC:US





    I hope at least minimally useful. In case of interest (€uribor free) ►►►►►►►.




    ☻/♫♪ ۞ [email protected]❣♆¥.pk Alert ۞ P▲ℕ❣☪ €MP¥R€
    /▌
    / \
    Leggi/Read: [email protected]❣♆¥ ♥ ® █║▌│█│║▌║▌║│█ © ❤ DISCLAIMER, IMO & Manthra
    Trading-Station - New F.o.L. Order
    K€SADDhAPHA'pe'KAMPA' €MP¥R€ $0UND $¥$T€M$ ❣❣❣
    [email protected]❣♆¥ €MP¥R€ $0UND $¥$T€M$ ♫ ❤® █║▌│█│║▌║▌║│█ ©❤ ♫


    Citazione Originariamente Scritto da scaparo Visualizza Messaggio
    ..................
    Personalmente, 3 per me hanno le caratteristiche che servono per sorreggere il tutto. A mio avviso, ripeto, questi titoli sono:
    G.MI - GS - HBC.
    ..............................
    Citazione Originariamente Scritto da scaparo Visualizza Messaggio
    Ultima modifica di Sal.Vi; 05-01-12 alle 15:23 Motivo: ❣ format & text corrections ❣

Accedi